Clinical Trials Browser

Withdrawn × OTHER × Ramucirumab × Clear all

NCT04179110 2022-02-22

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03739801 2020-03-27

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Locally Advanced Unresectable Gastric Adenocarcinoma